Work

Mechanism of Resistance to a Phase-II Idelalisib-Based Clinical Trial in CLL

Year: 2023

Type: article

Source: Cancer Letters

DOI: 10.1016/j.canlet.2023.216555

Authors: Murali K. Mamidi, Hasan Mahmud, Guru P. Maiti, Mariana T. Mendez, Stacey M. Fernandes, Sara K. Vesely, Jennifer Holter-Chakrabarty, Jennifer R. Brown, Asish K. Ghosh

Institutions: OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Dana-Farber Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389524747

FWCI:

Cites:

Cited by:

Related to: 10